Product/Composition:- | Dexketoprofen + Tramadol tablets |
---|---|
Strength:- | 25 mg dexketoprofen + 37.5 mg tramadol |
Form:- | Tablets |
Reference Brands:- | Enantyum(EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Dexketoprofen + Tramadol combines dexketoprofen’s inhibition of COX enzymes, reducing prostaglandin synthesis, with tramadol’s activation of opioid receptors and serotonin/norepinephrine reuptake inhibition. Benefits include effective relief from moderate to severe acute pain, rapid onset, and dual mechanisms for enhanced analgesia, with manageable side effects when used responsibly.
Dexketoprofen + Tramadol tablets are approved in the EU for managing moderate to severe acute pain, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, this combination is currently not approved or marketed. In the EU, regulatory approval requires comprehensive clinical data and pharmacovigilance plans. Both regions enforce strict prescribing regulations due to the opioid component. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We facilitate seamless market access for dexketoprofen + tramadol formulations, ensuring adherence to European standards for safe, effective analgesic therapy while navigating complex regulatory pathways effectively.